Our Mission:
Optimize.
Improving outcomes and quality of life with a minimally invasive alternative for ALL tricuspid valve regurgitation patients
Introduction
Triflo Cardiovascular is a Southern California – based biomedical company focused on delivering the best transcatheter system to treat tricuspid valve regurgitation patients regardless of the native valve’s size and anatomy. Setting aside conventional valve technologies, our engineers have honed in on the unique features of the tricuspid valve and the right heart. The result is the Tricuspid Flow Optimizer, a unique implantable device with a minimalistic footprint and polymer leaflets that work with the native anatomy. In tandem with the Optimizer, an intuitive and easy to use transfemoral delivery system was developed in collaboration with highly experienced interventional cardiologists. Following exhaustive testing, Triflo has started clinical evaluations of the Tricuspid Flow Optimizer.
Clinical Need
The tricuspid valve is one of four heart valves that is essential to maintain a unidirectional flow of blood through the heart, allowing it to efficiently pump blood throughout the body. Frequently, especially among the elderly, the tricuspid valve can start to fail and lead to a condition known as tricuspid regurgitation (TR) where blood flows backwards during the heart’s contraction. Depending on the severity of the backflow, individuals may experience symptoms such as fatigue, weakness, abdominal swelling, and palpitations. If TR becomes severe, it may be life threatening and require surgical intervention.
Tricuspid Valve Regurgitation (TR) Facts
>1.6 million elderly US patients diagnosed with moderate / severe TR
Moderate TR can progress and lead to serious symptoms, hospitalizations, and Heart Failure
Drug treatment cannot reverse TR and surgery may not be an option due to high risk
Consequently, treatment rates for severe symptomatic TR are very low
Patients need a better option
Our Solution
Designing the future of structural heart device. Triflo has been specifically ideated and designed for Tricuspid Regurgitation.
The Tricuspid Flow Optimizer features:
Intraoperatively Customizable
Severe regurgitation reduction regardless of size or shape of the native valve to treat wider patient segments.
Safe and Durable
Safety and biocompatibility with minimalistic design, secure fixation, and adaptive mini-valve with polymer leaflets.
Ease of Use
Ease of implementation with rapid learning curve using transfemoral delivery method.
Scalable Design
Simple scale-up and favorable production process considered since inception.
The Tricuspid Flow Optimizer is in development and is not available for sale or general clinical use anywhere in the world. As a permanent heart implant, it requires extensive testing to ensure safety and efficacy for human use.
